Results 101 to 110 of about 20,735 (212)

5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy [PDF]

open access: yes, 2017
The tumour-associated antigen 5T4 is an attractive target for cancer immunotherapy. However to date, reported 5T4-specific cellular immune responses induced by various immunisation platforms have been largely weak or non-existent.
Cappuccini, Federica   +4 more
core   +2 more sources

Erythema multiforme after Covishield/ ChAdOx1 vaccination [PDF]

open access: yesDermatologic Therapy, 2021
Rohit Sanjay Kothari   +5 more
openaire   +2 more sources

Mass‐Standardised Differential Antibody Binding to a Spectrum of SARS‐CoV‐2 Variant Spike Proteins: Wuhan, Alpha, Beta, Gamma, Delta, Omicron BA.1, BA.4/5, BA.2.75 and BA.2.12.1 Variants—Antibody Immunity Endotypes

open access: yesImmunology, Volume 177, Issue 4, Page 798-809, April 2026.
Fully quantitative, mass‐standardised, antibody responses to ten SARS‐CoV‐2 variants show significant variation in immunity profiles or endotypes. The incidence of the complete response to all variants is significantly improved after three vaccinations.
Philip H. James‐Pemberton   +6 more
wiley   +1 more source

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil [PDF]

open access: yes, 2021
Several COVID-19 vaccines have shown good efficacy in clinical trials, but there remains uncertainty about the efficacy of vaccines against different variants. Here, we investigate the efficacy of ChAdOx1 nCoV-19 (AZD1222) against symptomatic COVID-19 in
Bibi, Sagida   +8 more
core  

Booster vaccination against SARS-CoV-2 induces potent immune responses in people with human immunodeficiency virus [PDF]

open access: yes, 2022
Background People with human immunodeficiency virus (HIV) on antiretroviral therapy (ART) with good CD4 T-cell counts make effective immune responses following vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Abeywickrema, Movin   +50 more
core   +2 more sources

Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination [PDF]

open access: yesThe Lancet, 2021
Viktoria, Muster   +4 more
openaire   +2 more sources

Myelin Oligodendrocyte Glycoprotein-Associated Disorders Post-ChAdOx1 Vaccination

open access: yesCureus, 2022
ChAdOx1 nCoV-19 vaccine (AstraZeneca) has been associated with rare adverse events following vaccination such as thrombosis with thrombocytopenia syndrome, inflammatory myositis, and autoimmune encephalitis. Para-infectious or post-infectious myelin oligodendrocyte glycoprotein-associated disorders (MOGAD) have been reported in association with ...
openaire   +2 more sources

Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention

open access: yesMedComm, Volume 7, Issue 3, March 2026.
This review focuses on the clinical features, molecular mechanisms, treatment methods, and preventive measures of the VZV, with the aim of providing a theoretical basis for the development of new treatment and prevention methods for HZ. ABSTRACT Varicella zoster virus (VZV) is a ubiquitous human herpesvirus that establishes lifelong latency and causes ...
Lei Peng   +8 more
wiley   +1 more source

Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial

open access: yesEBioMedicine, 2022
Summary: Background: Intranasal vaccination may induce protective local and systemic immune responses against respiratory pathogens. A number of intranasal SARS-CoV-2 vaccine candidates have achieved protection in pre-clinical challenge models ...
Meera Madhavan   +21 more
doaj   +1 more source

CD56bright NK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B‐cell‐depleting therapy

open access: yesClinical &Translational Immunology, Volume 15, Issue 2, 2026.
Antibody response to vaccination in people with multiple sclerosis receiving B‐cell depletion therapy is associated with B‐cell frequency but not time since B‐cell depletion. Immunoregulatory CD56bright NK cells may negatively impact antibody responses in this group.
Griffith B Perkins   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy